Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

Phase 2

Completed

• Conditions: Breast Neoplasms
• Interventions: Drug: BIBW 2992

• Registration Number: NCT00431067
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-09
• Study First Submitted: 2007-02-02
• Study First Submitted QC: 2007-02-02
• Study First Posted: 2007-02-05
• Primary Completion: 2009-08
• Results First Submitted: 2013-08-08
• Status Verified: 2013-11
• Results First Submitted QC: 2013-11-06
• Results First Posted: 2013-12-23
• Last Update Submitted: 2014-06-03
• Last Update Posted: 2014-06-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

1. Male or female patients with confirmed diagnosis of Stage IIIB or IV HER2-positive metastatic breast cancer(HER2 2+ and FISH positive or HER2 3+).
2. Patients must have progressed following receipt of prior standard trastuzumab treatment or standard chemotherapy in conjunction with trastuzumab. Patients with visceral disease or rapid progression should not be included if they have not had previous chemotherapy in addition to trastuzumab. Patients who are intolerant to trastuzumab and who have received adequate chemotherapy and/or hormone therapy are eligible upon progression.
3. Age 18 years or older.
4. Life expectancy of at least four (4) months.
5. Written informed consent that is consistent with ICH-GCP guidelines.
6. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance Score 0, 1 or 2.
7. Patients should not have received treatment with chemotherapy or immune therapy within the last 4 weeks (2 weeks for trastuzumab). Patients should not have received treatment with hormone therapy within the last 2 weeks.
8. Patients must have recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies to CTC less than or equal to Grade 1.
9. Patients must have recovered from previous surgery.
10. Patients must have measurable disease as defined by RECIST criteria.

Exclusion criteria:

Exclusion Criteria

1. Active infectious disease.
2. Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea.
3. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.
4. Patients with active/symptomatic brain metastases. Patients with a history of treated brain metastases must have stable or normal MRI scan at screening and be at least three months post-radiation or surgery.
5. Cardiac left ventricular function with resting ejection fraction <50%.
6. Absolute neutrophil count (ANC) less than 1500 cells/mm3.
7. Platelet count less than 100 000 cells/mm3.
8. Bilirubin greater than 1.5 mg/dl (>26 micromol /L, SI unit equivalent).
9. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than three times the upper limit of normal.
10. Serum creatinine greater than 1.5 mg/dl (>132 micromol/L, SI unit equivalent).
11. Women and men (and their partners) who are sexually active and unwilling to use a medically acceptable method of contraception.
12. Pregnancy or breast-feeding.
13. Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy or hormone therapy (including LHRH agonists, or other hormones taken for breast cancer), or participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study. Treatment with bisphosphonates is allowed.
14. Prior treatment with an EGFR- or HER2 inhibiting drug (except trastuzumab).
15. Patients unable to comply with the protocol.
16. Active alcohol or drug abuse.
17. Patients with history of other malignancy (except for appropriately treated superficial basal cell skin cancer and surgically cured cervical cancer in situ) unless free of disease for at least 3 years.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
BIBW 2992	BIBW 2992	BIBW 2992 (Afatinib) once daily until progression

Primary Outcome Measures

Name	Time	Method
Objective Response (OR)	From first dose of study medication to response measurement, up to 34 month	Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria .

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS)	From first dose of study medication to the occurrence of progression or death whichever came first, up to 34 month	PFS was defined as the time from the first treatment to the occurrence of tumour progression or death, whichever came first. It was assessed according to RECIST criteria.
Overall Survival (OS)	From first dose of study medication to death or to the last date the patient was known to be alive, up to 34 month	OS was defined as the time from first treatment to death or to the last date the patient was known to be alive.
Time to RECIST Tumour Reponse	From first dose of study medication to time when OR measurement was taken.	The time to OR was the duration from the first treatment to the time when the measurement criteria for CR and/or PR were met according to RECIST criteria.
Duration of Confirmed OR	From first OR to time of progression or death	Duration of confirmed OR is measured from the time of first OR to the time of progression or death (or date of censoring for progression free survival).

Trial Locations

Locations (12)

1200.11.4 Boehringer Ingelheim Investigational Site; 🇺🇸 Santa Monica, California, United States

1200.11.7 Boehringer Ingelheim Investigational Site; 🇺🇸 Encinitas, California, United States

1200.11.3 Boehringer Ingelheim Investigational Site; 🇺🇸 Scottsdale, Arizona, United States

1200.11.1 Boehringer Ingelheim Investigational Site; 🇺🇸 Boston, Massachusetts, United States

1200.11.2 Boehringer Ingelheim Investigational Site; 🇺🇸 Tampa, Florida, United States

1200.11.5 Boehringer Ingelheim Investigational Site; 🇺🇸 Chapel Hill, North Carolina, United States

1200.11.4401 Boehringer Ingelheim Investigational Site; 🇬🇧 Bournemouth, United Kingdom

1200.11.4404 Boehringer Ingelheim Investigational Site; 🇬🇧 Poole, United Kingdom

1200.11.4403 Boehringer Ingelheim Investigational Site; 🇬🇧 Truro, United Kingdom

1200.11.4402 Boehringer Ingelheim Investigational Site; 🇬🇧 Crownhill, Plymouth, United Kingdom

1200.11.4406 Boehringer Ingelheim Investigational Site; 🇬🇧 Guildford, United Kingdom

1200.11.4405 Boehringer Ingelheim Investigational Site; 🇬🇧 London, United Kingdom